Medicines Co (MDCO) Stake Maintained by Sarissa Capital Management Lp; Fedex (FDX) Holder Ami Asset Management Has Decreased Position by $1.66 Million

May 17, 2018 - By Henry Gaston

The Medicines Company (NASDAQ:MDCO) Logo

Ami Asset Management Corp decreased its stake in Fedex Corporation (FDX) by 3.8% based on its latest 2017Q4 regulatory filing with the SEC. Ami Asset Management Corp sold 6,685 shares as the company’s stock declined 6.15% with the market. The hedge fund held 169,051 shares of the air freight and delivery services company at the end of 2017Q4, valued at $42.19 million, down from 175,736 at the end of the previous reported quarter. Ami Asset Management Corp who had been investing in Fedex Corporation for a number of months, seems to be less bullish one the $66.03 billion market cap company. The stock decreased 0.09% or $0.22 during the last trading session, reaching $247.12. About 1.10M shares traded. FedEx Corporation (NYSE:FDX) has risen 25.45% since May 17, 2017 and is uptrending. It has outperformed by 13.90% the S&P500.

Alex Denner increased its stake in Medicines Co (MDCO) by 9.7% based on its latest 2017Q4 regulatory filing with the SEC. Sarissa Capital Management Lp bought 170,000 shares as the company’s stock rose 23.35% while stock markets declined. The hedge fund run by Alex Denner held 1.92 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $52.55M, up from 1.75M at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Medicines Co for a number of months, seems to be bullish on the $2.36 billion market cap company. The stock increased 0.03% or $0.01 during the last trading session, reaching $32.13. About 858,135 shares traded. The Medicines Company (NASDAQ:MDCO) has declined 34.73% since May 17, 2017 and is downtrending. It has underperformed by 46.28% the S&P500.

Since December 7, 2017, it had 1 buy, and 3 insider sales for $783,400 activity. Shares for $574,200 were sold by KESSLER ARMIN M. CROUSE WILLIAM sold $241,950 worth of The Medicines Company (NASDAQ:MDCO) on Wednesday, March 21. $3.71 million worth of The Medicines Company (NASDAQ:MDCO) was sold by MEANWELL CLIVE on Friday, December 15.

Investors sentiment increased to 1.25 in Q4 2017. Its up 0.47, from 0.78 in 2017Q3. It improved, as 26 investors sold MDCO shares while 51 reduced holdings. 28 funds opened positions while 68 raised stakes. 89.44 million shares or 5.03% more from 85.15 million shares in 2017Q3 were reported. New York-based New York State Teachers Retirement Systems has invested 0.01% in The Medicines Company (NASDAQ:MDCO). Louisiana State Employees Retirement Sys holds 0.03% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 27,600 shares. California Pub Employees Retirement has invested 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO). California State Teachers Retirement System has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 108,795 shares. Endurant Cap Mngmt Ltd Partnership reported 41,200 shares. Hightower Llc stated it has 0% in The Medicines Company (NASDAQ:MDCO). Qs Invsts Lc reported 1,500 shares. Focused Wealth Mgmt reported 700 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,809 shares or 0% of all its holdings. 24,264 were reported by Teacher Retirement Of Texas. Cubist Systematic Strategies Limited Com invested 0.01% of its portfolio in The Medicines Company (NASDAQ:MDCO). Atria Limited Company, a North Carolina-based fund reported 10,856 shares. Iridian Asset Management Ltd Llc Ct has invested 0.5% in The Medicines Company (NASDAQ:MDCO). 2.06 million are held by Franklin Resources Incorporated. Comerica Bankshares invested 0.01% in The Medicines Company (NASDAQ:MDCO).

More notable recent The Medicines Company (NASDAQ:MDCO) news were published by: Streetinsider.com which released: “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” on May 07, 2018, also Fool.com with their article: “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” published on May 17, 2018, Fool.com published: “Alnylam Looks Forward” on May 08, 2018. More interesting news about The Medicines Company (NASDAQ:MDCO) were released by: Streetinsider.com and their article: “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” published on May 15, 2018 as well as Seekingalpha.com‘s news article titled: “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” with publication date: April 25, 2018.

Among 11 analysts covering The Medicines Co (NASDAQ:MDCO), 11 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. The Medicines Co had 37 analyst reports since August 28, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Wednesday, August 9. The rating was maintained by Oppenheimer with “Hold” on Monday, August 28. On Monday, November 16 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Market Perform” rating given on Monday, August 31 by Oppenheimer. H.C. Wainwright maintained The Medicines Company (NASDAQ:MDCO) on Tuesday, July 25 with “Buy” rating. The firm has “Buy” rating by Oppenheimer given on Wednesday, November 29. The stock of The Medicines Company (NASDAQ:MDCO) earned “Buy” rating by Chardan Capital Markets on Monday, March 21. The firm has “Neutral” rating by Citigroup given on Monday, August 14. The firm has “Neutral” rating by Citigroup given on Wednesday, July 26. The firm has “Buy” rating by Citigroup given on Monday, January 22.

Since January 2, 2018, it had 1 buying transaction, and 4 selling transactions for $45.54 million activity. Shares for $31.74M were sold by SMITH FREDERICK W on Wednesday, April 18. $1.12 million worth of FedEx Corporation (NYSE:FDX) was sold by WALSH PAUL S. $802,405 worth of FedEx Corporation (NYSE:FDX) shares were sold by STEINER DAVID P. Shares for $11.89M were sold by BRONCZEK DAVID J on Tuesday, January 2.

Analysts await FedEx Corporation (NYSE:FDX) to report earnings on June, 19. They expect $5.72 EPS, up 34.59% or $1.47 from last year’s $4.25 per share. FDX’s profit will be $1.53 billion for 10.80 P/E if the $5.72 EPS becomes a reality. After $3.72 actual EPS reported by FedEx Corporation for the previous quarter, Wall Street now forecasts 53.76% EPS growth.

Investors sentiment increased to 1.21 in Q4 2017. Its up 0.14, from 1.07 in 2017Q3. It increased, as 45 investors sold FDX shares while 366 reduced holdings. 137 funds opened positions while 361 raised stakes. 193.75 million shares or 3.04% less from 199.84 million shares in 2017Q3 were reported. Douglass Winthrop Advsrs Ltd Liability Company stated it has 0.21% in FedEx Corporation (NYSE:FDX). Roof Eidam & Maycock Adv has invested 0.58% in FedEx Corporation (NYSE:FDX). Williams Jones And Associates Limited Liability Co has 186,858 shares. Maryland-based Price T Rowe Assocs Md has invested 0.04% in FedEx Corporation (NYSE:FDX). Lee Danner & Bass accumulated 52,987 shares. Mirae Asset Investments Com Limited stated it has 1,364 shares. Strs Ohio holds 0.19% or 177,038 shares. Aviance Prtn Ltd Com has 965 shares. Perkins Coie Trust owns 190 shares or 0.02% of their US portfolio. Maine-based Bangor Fincl Bank has invested 0.33% in FedEx Corporation (NYSE:FDX). Nomura has invested 0.05% in FedEx Corporation (NYSE:FDX). Oppenheimer & has 0.12% invested in FedEx Corporation (NYSE:FDX) for 18,256 shares. Hightower Ltd Liability holds 0.3% or 147,928 shares. National Mutual Federation Of Agricultural Cooperatives owns 16,000 shares. Illinois-based Interocean Capital Limited has invested 0.38% in FedEx Corporation (NYSE:FDX).

Among 37 analysts covering FedEx (NYSE:FDX), 26 have Buy rating, 1 Sell and 10 Hold. Therefore 70% are positive. FedEx had 117 analyst reports since August 14, 2015 according to SRatingsIntel. Oppenheimer maintained it with “Buy” rating and $22900 target in Wednesday, June 14 report. The company was maintained on Sunday, February 11 by Robert W. Baird. The rating was downgraded by UBS on Friday, September 15 to “Neutral”. The stock of FedEx Corporation (NYSE:FDX) earned “Buy” rating by UBS on Wednesday, June 21. The stock of FedEx Corporation (NYSE:FDX) has “Buy” rating given on Wednesday, June 21 by Robert W. Baird. Oppenheimer maintained the stock with “Outperform” rating in Thursday, September 17 report. Seaport Global initiated the shares of FDX in report on Tuesday, June 6 with “Hold” rating. KeyBanc Capital Markets maintained the stock with “Buy” rating in Wednesday, December 20 report. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, September 21. The rating was downgraded by Zacks on Monday, September 7 to “Sell”.

Ami Asset Management Corp, which manages about $1.42B and $1.45B US Long portfolio, upped its stake in Corcept Therapeutics Inc. (NASDAQ:CORT) by 97,867 shares to 625,382 shares, valued at $11.29 million in 2017Q4, according to the filing.

FedEx Corporation (NYSE:FDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: